Aptamer Group, the developer of Optimer reagents and therapeutics, has extended their current agreement with AstraZeneca. This agreement will build upon the existing collaboration to evaluate the potential of using Optimer-based strategies to target renal cells and explore the feasibility of developing next-generation drug delivery vehicles, Optimer-drug conjugates.   Optimers are optimized aptamer reagents. Based on oligonucleotide molecules Optimers can bind specifically to a target molecule ...